title: Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
abstract: OBJECTIVE
  The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL.
  
  
  METHODS
  Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram-a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment.
  
  
  RESULTS
  There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status.
  
  
  CONCLUSIONS
  We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wwierda@mdanderson.org
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.forename: Kim-Anh
authors.initials: KA
authors.lastname: Do
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Deborah
authors.initials: D
authors.lastname: Thomas
authors.forename: Charles A
authors.initials: CA
authors.lastname: Koller
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.forename: Susan
authors.initials: S
authors.lastname: Lerner
authors.forename: Ellen
authors.initials: E
authors.lastname: Schlette
authors.forename: Lynne
authors.initials: L
authors.lastname: Abruzzo
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D017353:Gene Deletion; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007770:L-Lactate Dehydrogenase / Q000235:genetics / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009154:Mutation; D049451:Nomograms; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D013781:Texas; D013997:Time Factors; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D007143:Immunoglobulin Heavy Chains; D007770:L-Lactate Dehydrogenase; D051746:ZAP-70 Protein-Tyrosine Kinase